Dupilumab for a 5‐year‐old child with prurigo nodularis
October 2023
in “
JDDG Journal der Deutschen Dermatologischen Gesellschaft
”
TLDR Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
A 5-year-old Taiwanese girl with prurigo nodularis (PN) showed significant improvement after being treated with off-label dupilumab. Her Itch Numeric Rating Scale decreased from 8 to 2 over six months, and her skin lesions were nearly in complete remission. No adverse effects were reported. Dupilumab, which blocks the Th2 signal transduction pathway, is effective in treating PN by targeting IL-4 and IL-13. While dupilumab is licensed for PN in the USA and Europe, more research is needed to confirm its efficacy and safety in children, as current data is limited.
